Prescient Therapeutics (PTX) has unveiled a novel adjuvant for enhancing cellular immunotherapy.
The CellPryme-A product was designed to be administered to cancer patients as an intravenous infusion in combination with cellular immunotherapy, such as PTX’s CAR-T cell therapy. This is used to address the hostile tumour microenvironment that cellular immunotherapies face.
CellPryme-A can be administered either before or alongside cellular immunotherapy.
Prescient said in animal models, CellPryme-A had been shown to reduce the number of suppressive regulatory T cells surrounding solid tumours that counteracted the effectiveness of CAR-T and other cancer therapies.
While CellPrymeA demonstrated superior tumour killing and host survival in pre-clinical studies, its effects were even greater when used together with Prescient’s CAR-T manufacturing technology, CellPryme-M.
The company presented this new data at the seventh annual CAR-TCR Summit in Boston.
Prescient Managing Director and CEO Steven Yatomi-Clarke said the company was delighted to “finally” unveil CellPryme-A as a distinct but complementary addition to CellPryme-M.
“Together with Prescient’s next-generation CAR platform, OmniCAR, Prescient has placed itself enviably at the forefront of cellular immunotherapy by creating technologies that overcome the challenges facing the field,” Mr Yatomi-Clarke said.
The company said CellPryme-Awas now ready for clinical testing and could be incorporated into clinical studies of existing cell therapies.
Prescient Therapeutics was down 1.35 per cent and trading at 18 cents at 1:29 pm AEST.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。